Alector ALEC 深 沪
交易中 01-28 10:47:22 美东时间
1.92
-0.030
-1.54%
华盛通- 最 高1.965
- 今 开1.96
- 成交量 11.96万股
- 最 低 1.85
- 昨 收 1.95
- 总市值 1.94亿
- 52周最高 3.3999
- 市盈率 静 --
- 换手率 0.12%
- 52周最低 0.87
- 委 比 8.31%
- 总股本 1.01亿
- 历史最高 43.32
- 量 比 1.31
- 振 幅 5.90%
- 历史最低 0.87
- 每 手 1
- 风险率 0.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alector Ends Latozinemab Continuation Study: Reading the Signals for ALEC Investors
Alector ($ALEC) announced an update on their ongoing clinical study. Alector’s ...
01-22 00:31
Adimab Records Another Year of Double-Digit Clinical Program Growth
– 11 New Clinical Programs in 2025 –– 6 Partner Programs Have Reached the Marke...
01-14 01:33
Alector appoints Neil Berkley as chief financial officer
Alector (ALEC) said on Friday that Neil Berkley has been appointed CFO, effective December 10, 2025. Berkley has served as Alector’s Chief Business Officer (CBO) since March 2024, and CBO and Interim ...
2025-12-13 05:22
Alector to Participate in the Bank of America CNS Therapeutics Conference
Alector, Inc. (Nasdaq: ALEC), a biotech company developing therapies for neurodegenerative diseases, announced that its management will participate in a fireside chat at the Bank of America CNS Therapeutics Conference on December 8, 2025. The event will be available via webcast on the company’s Investors page, with a 90-day replay. Alector focuses on counteracting neurodegenerative diseases like Alzheimer’s and Parkinson’s through innovative ther...
2025-12-01 21:05
Alector Reports Third Quarter 2025 Financial Results and Provides Business Update
Alector reported Q3 2025 financials with $291.1M in cash, enabling operations through 2027. Key updates include advancing AL137 (anti-amyloid beta antibody for Alzheimer's) and AL050 (GCase ERT for Parkinson's) toward IND filings in 2026 and 2027, respectively. The company is also advancing ABC-enabled siRNA programs for neurodegenerative diseases. An independent interim analysis for the PROGRESS-AD trial of nivisnebart in early Alzheimer's is pl...
2025-11-06 21:05
美股大行评级 | 超配！万事达、Visa、Block获多家机构首予评级；奈飞、德州仪器遭多家机构下调目标价
今日重点评级关注：Canaccord Genuity：维持ATAI Life Sciences"买入"评级，目标价从11美元升至14美元；麦格理：维持Cleanspark"跑赢大市"评级，目标价从20美元升至30美元
2025-10-23 10:06
尾盘：美股跌幅扩大 科技股跌幅领先
北京时间10月23日凌晨，美股周三尾盘跌幅扩大，科技股领跌。芯片板块普遍走低，纳指下跌逾300点。市场继续关注美股财报与美联储利率政策前景。 道...
2025-10-23 02:59
午盘：美股维持下跌局面 纳指下跌约200点
北京时间10月23日凌晨，美股周三午盘维持下跌局面。芯片板块普遍走低，纳指下跌约200点。市场继续关注美股财报与美联储利率政策前景。 道指跌1...
2025-10-23 00:12
Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce
Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; Alector cuts 49% of staff.
2025-10-23 00:07
TD Cowen Downgrades Alector to Hold
TD Cowen analyst Yaron Werber downgrades Alector (NASDAQ:ALEC) from Buy to Hold.
2025-10-22 23:12
